Today in a letter to the Department of Justice (DOJ) the AHA raised concerns about the proposed Anthem acquisition of Cigna focusing on the impact of Anthem’s affiliation with the Blue Cross Blue Shield System.

The letter states:

“Previous investigations also suggest that increased Blue plan market power will raise, not lower, premiums to consumers. We would expect that same impact on premiums in any state with a dominant or near-dominant Blue plan that gains any additional market power as a result of this acquisition.  And, no speculative claim of efficiency gains by the parties can offset the likelihood that premiums will increase for consumers as a result of this transaction.

Finally, the temptation for dominant plans to abuse their market power will only increase as a result of this acquisition.  Some dominant Blue plans already have the financial and other means to undermine or defeat entry or expansion by other plans, even established plans.  Eliminating a national competitor better able to withstand the onslaught of a variety of anticompetitive tactics will almost certainly embolden this conduct, thereby harming, perhaps irreparably, any chance of increasing competition and consumer choice.”

The AHA continues to ask DOJ to challenge this acquisition and examine the impact on competition, including the increase in barriers to competition in states where Anthem is not the Blue plan because we believe this deal threatens to undermine reform by discouraging or blocking entirely new entry and entrenching already dominant insurers across the nation.

Perspective
Public
May is Mental Health Awareness Month, a time to elevate a conversation that hospitals and health systems live every day. Behavioral health is inseparable from…
Headline
The AHA submitted a statement for the record to the House Ways and Means Committee for its April 28 hearing with health system CEOs.In the statement, the AHA…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The administration Apri 23 reached a most-favored-nation drug pricing agreement with Regeneron, the maker of the popular cholesterol medicine Praluent. This is…
Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
Rep. Blake Moore, R-Utah, vice chair, House Republican Conference and member of the House Ways and Means Committee and its Subcommittee on Health, joined Bill…